 <h1>Baricitinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to baricitinib: oral tablets</i></p><h3>Warning</h3><p><ul>
Serious Infections
<li>
Serious, sometimes fatal infections including tuberculosis (pulmonary or extrapulmonary disease), bacterial and viral infections, invasive fungal infections (may be disseminated), and other opportunistic infections reported.&lt;sup&gt;1&lt;/sup&gt;  (See Infectious Complications under Cautions.)</li></ul></p><ul>
Serious Infections
<li>
Serious, sometimes fatal infections including tuberculosis (pulmonary or extrapulmonary disease), bacterial and viral infections, invasive fungal infections (may be disseminated), and other opportunistic infections reported.&lt;sup&gt;1&lt;/sup&gt;  (See Infectious Complications under Cautions.)</li></ul><p>
<li>
Carefully consider risks and benefits prior to initiating baricitinib therapy in patients with chronic or recurring infections.&lt;sup&gt;1&lt;/sup&gt;</li></p><p>
<li>
Evaluate patients for latent tuberculosis infection prior to and periodically during treatment; if indicated, initiate appropriate antimycobacterial regimen prior to initiating baricitinib therapy.&lt;sup&gt;1&lt;/sup&gt;</li></p><p>
<li>
Closely monitor patients for infection, including active tuberculosis in those with a negative test for latent tuberculosis, during and after treatment.&lt;sup&gt;1&lt;/sup&gt;  If serious infection develops, interrupt baricitinib therapy until infection is controlled.&lt;sup&gt;1&lt;/sup&gt;</li></p><p></p><p><ul>
Malignancies
<li>
Lymphoma and other malignancies reported.&lt;sup&gt;1&lt;/sup&gt;  (See Malignancies and Lymphoproliferative Disorders under Cautions.)</li></ul></p><ul>
Malignancies
<li>
Lymphoma and other malignancies reported.&lt;sup&gt;1&lt;/sup&gt;  (See Malignancies and Lymphoproliferative Disorders under Cautions.)</li></ul><p></p><p><ul>
Thrombosis
<li>
Serious, sometimes fatal thromboembolic events, including DVT, PE, and arterial thrombosis, reported.&lt;sup&gt;1&lt;/sup&gt;  Promptly evaluate patients with symptoms of thrombosis.&lt;sup&gt;1&lt;/sup&gt;  (See Thromboembolic Events under Cautions.)</li></ul></p><ul>
Thrombosis
<li>
Serious, sometimes fatal thromboembolic events, including DVT, PE, and arterial thrombosis, reported.&lt;sup&gt;1&lt;/sup&gt;  Promptly evaluate patients with symptoms of thrombosis.&lt;sup&gt;1&lt;/sup&gt;  (See Thromboembolic Events under Cautions.)</li></ul><p></p><p>Side effects include:</p><p>Upper respiratory tract infection,  nausea,  herpes simplex,  herpes zoster.   </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to baricitinib: oral tablet</i></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytosis, anemia</p><p><b>Uncommon</b> (0.1% to 1%): Neutropenia</p><p><b>Frequency not reported</b>: Lymphocytosis (occurs at higher rates in the elderly)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Herpes zoster, herpes simplex (e.g., eczema herpeticum, herpes simplex, ophthalmic herpes simplex, oral herpes), influenza<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, rheumatoid arthritis, back pain, muscle spasm, myalgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision</p><p><b>Uncommon</b> (0.1% to 1%): Cataract<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypercholesterolemia (34%)</p><p><b>Uncommon</b> (0.1% to 1%): Hypertriglyceridemia, weight gain, creatine phosphokinase increased to greater than 5 times the upper limit of normal (ULN)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Insomnia, depression<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection, benign prostatic hyperplasia</p><p><b>Uncommon</b> (0.1% to 1%): Cystitis, erectile dysfunction, vulvovaginal candidiasis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): ALT increased greater than or equal to 3 times the upper limit of normal (ULN)</p><p><b>Uncommon</b> (0.1% to 1%): AST increased greater than or equal to 3 times the upper limit of normal (ULN), abnormal hepatic function<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infections (e.g., sinusitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, tonsillitis, tracheitis) (15%)</p><p><b>Common</b> (1% to 10%): Bronchitis, sinusitis, rhinitis, cough</p><p><b>Uncommon</b> (0.1% to 1%): Tonsillitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, pyrexia, peripheral edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, coronary artery disease<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, rash<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, gastroenteritis, dyspepsia, upper abdominal pain, constipation, vomiting, oropharyngeal pain, stomatitis, abdominal discomfort, gastroesophageal reflux disease<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company, Indianapolis, IN. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs for the treatment of rheumatoid arthritis (RA)?</li>
<li>Is baricitinib (Olumiant) being used to treat COVID-19?</li>
<li>What type of drug is Olumiant (baricitinib)?</li>
</ul><h2>More about baricitinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: antirheumatics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Baricitinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Rheumatoid Arthritis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>